Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.

Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA.

J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.

2.

A conserved transcriptional response to intranasal Ebola virus exposure in nonhuman primates prior to onset of fever.

Speranza E, Bixler SL, Altamura LA, Arnold CE, Pratt WD, Taylor-Howell C, Burrows C, Aguilar W, Rossi F, Shamblin JD, Wollen SE, Zelko JM, Minogue T, Nagle E, Palacios G, Goff AJ, Connor JH.

Sci Transl Med. 2018 Mar 28;10(434). pii: eaaq1016. doi: 10.1126/scitranslmed.aaq1016.

PMID:
29593102
3.

DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.

Cashman KA, Wilkinson ER, Wollen SE, Shamblin JD, Zelko JM, Bearss JJ, Zeng X, Broderick KE, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):3010-3019. doi: 10.1080/21645515.2017.1382780. Epub 2017 Nov 14.

4.

A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.

Cashman KA, Wilkinson ER, Shaia CI, Facemire PR, Bell TM, Bearss JJ, Shamblin JD, Wollen SE, Broderick KE, Sardesai NY, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2902-2911. doi: 10.1080/21645515.2017.1356500. Epub 2017 Oct 18.

5.

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.

Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM.

Science. 2016 Mar 4;351(6277):1078-83. doi: 10.1126/science.aad5788. Epub 2016 Feb 18.

6.

Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.

Trefry JC, Wollen SE, Nasar F, Shamblin JD, Kern SJ, Bearss JJ, Jefferson MA, Chance TB, Kugelman JR, Ladner JT, Honko AN, Kobs DJ, Wending MQ, Sabourin CL, Pratt WD, Palacios GF, Pitt ML.

Viruses. 2015 Dec 19;7(12):6739-54. doi: 10.3390/v7122969.

7.

Dose Response of MARV/Angola Infection in Cynomolgus Macaques following IM or Aerosol Exposure.

Johnston SC, Lin KL, Twenhafel NA, Raymond JL, Shamblin JD, Wollen SE, Wlazlowski CB, Wilkinson ER, Botto MA, Goff AJ.

PLoS One. 2015 Sep 28;10(9):e0138843. doi: 10.1371/journal.pone.0138843. eCollection 2015.

8.

Experimental aerosolized guinea pig-adapted Zaire ebolavirus (variant: Mayinga) causes lethal pneumonia in guinea pigs.

Twenhafel NA, Shaia CI, Bunton TE, Shamblin JD, Wollen SE, Pitt LM, Sizemore DR, Ogg MM, Johnston SC.

Vet Pathol. 2015 Jan;52(1):21-5. doi: 10.1177/0300985814535612. Epub 2014 May 14.

PMID:
24829285

Supplemental Content

Loading ...
Support Center